Regulatory Blog

Generative artificial intelligence (GenAI) is creating new opportunities for medical devices while also introducing regulatory challenges that may differ from traditional software and AI-enabled devices. The U.S. Food and Drug Administration (FDA) is seeking public input on how GenAI-enabled medical devices could be evaluated and monitored while maintaining reasonable assurance of safety and effectiveness. The FDA’s Center for Devices and Radiological Health (CDRH), through i

The U.S. Food and Drug Administration (FDA) has marked a significant milestone in its digital transformation journey by announcing the...